報價延遲最少15分鐘:2025/06/04 03:41 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.81 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-18.04/-16.02
|
|
企業價值
32.81M
|
| 資產負債 |
|
每股賬面淨值
3.02
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 03:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. |